Date: 29 and 30 April
Hour: 9 a.m. to 5 p.m.
Venue: Congress Centre, Técnico – Alameda campus
The Annual Meeting of the NOSEVAC consortium in 2025 is going to be held in Portugal, at IST Congress Centre. The NOSEVAC project is funded by the European Union, aiming at developing and evaluating innovative nasal vaccine platforms as a novel approach to prevent the earliest stage of infection, thereby inhibiting upper respiratory tract colonisation, transmission and disease.
Under the European Vaccine Initiative (EVI) coordination, the NOSEVAC project builds on a unique consortium of 13 complementary teams from the EU, UK and Switzerland. IST-ID, Portugal is the latest member joining the consortium in 2024, with Work-Package 8, and funding of 500K EUR over 4 years: Mathematical modelling of bioprocesses involved in the respiratory tract colonisation and nasal vaccines, led by Erida Gjini, a researcher at the Center for Computational and Stochastic Mathematics (CEMAT), a Técnico research unit.
By developing mathematical and quantitative modelling platforms for nasal vaccine research, the IST-ID team aims to help enhance the understanding of approaches for the prevention and the reduction of nasal colonisation of respiratory pathogens. The project focuses on four major respiratory pathogens: Streptococcus pneumoniae or pneumococcus, Bordetella, influenza virus, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for diseases with major impact on public health.
The Annual meeting kicks off with a public session “Predict, prevent, protect: the science and strategy of vaccine development” scheduled for 29 April 2025, from 9 a.m. to 11 a.m. in room 02.1 at IST Congress Centre.
